To The Moon

Pfizer looking into data suggesting a potential link to sickle-cell complications and 'fatal events'. Pfizer Inc. said late Wednesday it was withdrawing a sickle-cell drug from markets worldwide and discontinuing clinical trials of the treatment after it investigates data suggesting a potential link to sickle-cell complications and "fatal events.". "Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle-cell patient population," the pharma giant said in a statement."The data suggest an imbalance in vaso-occlusive crises and fatal events which require further assessment." Vaso-occlusive crises are a relatively common complication of sickle-cell anemia.Pfizer said it does not expect the voluntary action to impact its full-year 2024 financial guidance.Pfizer has notified regulatory authorities about its decision to withdraw the treatment while it further reviews the available data a

Pfizer looking into data suggesting a potential link to sickle-cell complications and 'fatal events'. Pfizer Inc. said late Wednesday it was withdrawing a sickle-cell drug from markets worldwide and discontinuing clinical trials of the treatment after it investigates data suggesting a potential link to sickle-cell complications and "fatal events.". "Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle-cell patient population," the pharma giant said in a statement."The data suggest an imbalance in vaso-occlusive crises and fatal events which require further assessment." Vaso-occlusive crises are a relatively common complication of sickle-cell anemia.Pfizer said it does not expect the voluntary action to impact its full-year 2024 financial guidance.Pfizer has notified regulatory authorities about its decision to withdraw the treatment while it further reviews the available data a